Klin Farmakol Farm. 2010;24(2):66-70

Importance of Drug Utilization Studies in Pharmacoepidemiology on Examples of Longitudinal Studies

Eva Tlustá1, Jiří Vlček1,2,3, Andrea Kučerová-Lamková1, Lenka Buriánková1, Zdeněk Vitásek4
1Katedra sociální a klinické farmacie, Farmaceutická fakulta v Hradci Králové
22. interní klinika Fakultní nemocnice v Hradci Králové
3Národní reprezentant ESAC
4Zaměstnanecká pojišťovna Škoda

of Proton Pump Inhibitors, Antibiotics and Metformin

Drug utilization studies serve as a tool for estimation of drug exposure in population as well as for evaluation of the influence of regulatory

interventions, marketing strategies and guidelines on the drug on the market. For drug utilization studies the ATC/DDD methodology is

widely used and recommended by the WHO. In our study the database of the SUKL (period 1993–2008) and health insurance company

(2006–2007) was used, and consumption of proton pump inhibitors (PPI), antibiotics and metformin was assessed. Drug utilization was

expressed as the number of defined daily doses (DDD) per 1000 individuals per day (DID).The rapid increase in utilization of PPI was demonstrated

with omeprazole as the most frequently used PPI. Also consumption of metformin increased more than twice in the period

from 2001 to 2008. In the group of antibiotics penicillines were still the most frequently prescribed, mainly amoxicillin in combination

with clavulanic acid. In the year 2008 the combined amoxicillin accounted for 51 % of utilization of all penicillines. The consumption of

macrolides was increasing, the increase represented mainly by clarithromycin, to a lesser extent by azithromycin.

Keywords: drug utilization, ATC/DDD methodology, proton pump inhibitors, antibiotics, metformin

Published: July 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tlustá E, Vlček J, Kučerová-Lamková A, Buriánková L, Vitásek Z. Importance of Drug Utilization Studies in Pharmacoepidemiology on Examples of Longitudinal Studies. Klin Farmakol Farm. 2010;24(2):66-70.
Download citation

References

  1. Vlček J. Farmakoepidemiologie In: Vlček J, Macek K, Dalecká R. Základy farmakoepidemiologie, farmakoekonomiky a farmakoinformatiky. Praha: Remedia, s.r.o., 2005: 6-41.
  2. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC/ DDD). Oslo. URL: http://www.who.int/classifications/atcddd/ en. (poslední aktualizace 2003).
  3. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2010. URL: http://www.whocc.no/atc_ ddd_index/(poslední aktualizace 27. 10. 2009).
  4. Stichele RHV, Elseviers MM, Ferech M, Blot S, Goossens H, the ESAC Project Group. European Surveillance of Antimicrobial Consumption (ESAC). Data Collection Performance and Methodological Approach. Br J Clin Pharmacol 2004; 58: 419-428. Go to original source... Go to PubMed...
  5. Ferech M, Coenen S, Malhotra-Kumar S, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother 2006; 58: 401-407. Go to original source... Go to PubMed...
  6. Gorecká K, Linhartová A, Vlček J, Tilšer I. Cardiovascular drug utilisation and socio-economic inequalities in 20 districts of the Czech Republic. Eur J Clin Pharmacol 2005; 61: 417-423. Go to original source... Go to PubMed...
  7. Vlček J, Stichele RHV, Perlík F, et al. Integrating drug utilisation studies in wider Europe, EURODURG meeting 2001. Galen 2001: 191.
  8. Gorecká K, Hejdová M, Stichele RHV, et al. Abstracts on drug utilization research at seven International Conferences on Pharmacoepidemiology (ICPE): 1996-2002; Pharmacoepidemiol Drug Safety 2004; 13: 621-622. Go to original source... Go to PubMed...
  9. Kučera Z, Vlček J, Hejdová M. Theoretical exposure of chronically treated patients to lipid lowering agents, Pharmacoepidemiol Drug Safety 2005; 14: 61-67. Go to original source... Go to PubMed...
  10. Vlček J, Šleszarová P, Pozlerová E, Kotlář J, Bláha V, Mashburn J. The antibiotic resistance survey: a preliminary report on the drug utilization evaluation study at the University Teaching Hospital, Charles University, Czech Republic. Pharmacoepidemiol Drug Safety 2000; 9: 237-243. Go to original source...
  11. Urbanek K, Kolar M, Strojil J, Koukalova D, Cekanova L, Hejnar P. Utilization of fluoroquinolones and Escherichia coli resistance in urinary tract infection: inpatients and outpatients. Pharmacoepidemiol Drug Safety 2005; 14: 741-745. Go to original source... Go to PubMed...
  12. Garía-Rey C, Martín-Herrero JE, Baquero F. Antibiotic consumption and generation of resistence in Streptococcus pneumonia: the paradoxical impact of quinolones in a complex selective landscape. Clin Microbiol Infect 2006; 12(Suppl. 3): 55-56. Go to original source... Go to PubMed...
  13. Kolář M, Urbánek K, Vágnerová I, Koukalová D. The influence of antibiotic use on the occurrence of vancomycin-resistant enterococci. J Clin Pharm Ther 2006; 31: 67-72. Go to original source... Go to PubMed...
  14. Goossens H, Ferech M, Stichele RHV, Elseviers M, ESAC Project Group. Outpatient antibiotic use in Europe and association with resistence: a cross-national database study. Lancet 2005; 365: 579-587. Go to original source...
  15. Roux C, Briot K, Gossec L, et al. Increase in vertebral fracture risk in postmenopausal women using omeprazole. Calcif Tissue Int 2009; 84: 13-19. Go to original source... Go to PubMed...
  16. Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296: 2947-2953. Go to original source... Go to PubMed...
  17. Laheij RJF, Sturkenboom MC, Hassing R-J, et al. Risk of community-acquired pneumonia and use of gastric acidsuppressive drugs. JAMA 2004; 292: 1955-1960. Go to original source... Go to PubMed...
  18. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-955. Go to original source... Go to PubMed...
  19. Marešová V. Kde nejčastěji chybujeme při předepisování antibiotik? Prakt lékáren 2009; 5: 195-196.
  20. Bergman M, Huikko S, Huovinen P, Paakkari P, Seppälä H; Finnish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and azithromycin use are linked to increased macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 3646-3650. Go to original source... Go to PubMed...
  21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patiens with type 2 diabetes (UKPDS 34). Lancet 1998; 12: 854-865. Go to original source...
  22. Nathan DM, Buse JB, Davidson MB, et al. Professional Practice Committee, American Diabetes Association, European Association for the Study of Diabetes. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721. Go to original source... Go to PubMed...
  23. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association, European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193-203. Go to original source... Go to PubMed...
  24. Česká diabetologická společnost. Doporučený postup péče o diabetes mellitus 2. typu (aktualizace 2009). URL: http://www.diab.cz/modules/Standardy/dm2_2009.pdf (cited 25. 2. 2010).
  25. Kořístková B, Grundmann M. Metodika studia spotřeb léků. Klin Farmakol Farm 2006; 20: 219-222.
  26. R?nning M, Blix HS, Harb? BT, Str?m H. Different versions of the anatomical therapeutic chemical classification system and the defined daily dose-are drug utilization data comparable? Eur J Clin Pharmacol 2000; 56: 723-727. Go to original source... Go to PubMed...
  27. WHO Collaborating Centre for Drug Statistics Methodology. DDD alterations from 1982-2010. URL: http://www.whocc.no/atc_ddd_alterations__cumulative_/ddd_alterations/(cited 23. 2. 2010).




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.